Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: J Magn Reson Imaging. 2015 Apr 24;42(6):1656–1665. doi: 10.1002/jmri.24929

Table 2.

Patients’ and lesions’ characteristics

Total patients: 21 N (%)
Female 21 (100)
Mean age in years ± SD (range) 51.3 ± 9.1 (41–70)
Indication for MRI
  Staging 15 (71.4)
  Diagnostic for unclear finding 6 (28.6)

Total lesions: 30
Lesion size in centimeters (mean ± SD) 2.63 ± 2.04
    Range 0.6 – 8.5
Background enhancement
  No 1 (3.3)
  Minimal 11 (36.7)
  Mild 3 (10.0)
  Moderate 6 (20.0)
  Marked 9 (30.0)
Initial type of pathology
  CNB 24 (80.0)
  Imaging / No biopsy 5 (16.7)
  Mastectomy for other lesion 1 (3.3)
Clip present
  Yes 15 (50.0)
  No 15 (50.0)
Initial diagnosis category
  Benign 10 (33.3)
    - Cyst − 5
    - Fibrocystic changes − 2
    - UDH − 1
    - Adenosis − 1
    - Fibroadenoma − 1
  High risk 3 (10.0)
    - ADH −1
    - ALH −1
    - Papilloma −1
  In situ carcinoma 3 (10.0)
    - DCIS − 3
  Invasive carcinoma 14 (46.7)
  - IDC − 14
Invasive breast cancer grade
  Nottingham grade 1 2 (14.3)
  Nottingham grade 2 4 (28.6)
  Nottingham grade 3 8 (57.1)
Associated DCIS with invasive carcinoma
  Yes 11 (78.6)
  No 3 (21.4)
ER status
  Positive 9 (56.3)
  Negative 6 (37.5)
  Unknown 1 (6.3)
PR status
  Positive 8 (50.0)
  Negative 7 (43.8)
  Unknown 1 (6.3)
HER2-Neu status
  Positive 2 (13.3)
  Negative 11 (73.3)
  Unknown 2 (13.3)

Abbreviations: SD: standard deviation; MRI: magnetic resonance imaging; CNB: core needle biopsy; UDH: usual type ductal hyperplasia; DCIS: ductal carcinoma in situ; IDC: invasive ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; HER2-Neu: human epidermal growth factor receptor 2.